Evaluating the effects of 5‐aminosalicylic acid on tofacitinib treatment in ulcerative colitis

Concomitant 5-ASA use reduced the risk of relapse in patients on 5 mg tofacitinib BID, suggesting benefits at lower doses. However, no significant benefit was observed with 5-ASA use in those 10 mg tofacitinib BID.